A Phase 3 interventional study of Vedolizumab and Adalimumab placebo in Colitis, Ulcerative, sponsored by Takeda. Completed at 330 sites in 34 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-01-28.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing vedolizumab in Colitis, Ulcerative — 5 open to participants now, 9 under way, 6 of them phase 3. vedolizumab · Colitis, Ulcerative.
Among the 38 studies testing vedolizumab in Colitis, Ulcerative, this one is the 4th largest by enrollment, is one of 3 that started in 2015, is one of 14 in phase 3, and was the 6th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →5 of the 38 studies testing vedolizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:
Takeda · Sites in United States, Belgium, Bulgaria and 11 more countries
Ages 2–17
Takeda · Sites in United States
Ages 18–80
Takeda · Sites in United States, Belgium, Bulgaria and 13 more countries
Ages 2–17
Takeda · Sites in United States, Australia, Belgium and 15 more countries
Ages 2+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 771 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 110 across the 38 interventional studies. Of the 23 that completed or were terminated, 16 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 38 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
68 studies in Colitis, Ulcerative by Takeda: 6 open now, 10 under way, 5 of them phase 3. Of 54 finished, 35 (65%) have results posted.
Among the 68 studies in Colitis, Ulcerative by Takeda, this one is the 4th largest by enrollment of the 43 interventional ones that give a count, is one of 4 that started in 2015, is one of 21 in phase 3, and was the 18th registered.
Takeda’s Colitis, Ulcerative studies by the year they started, since 2003.
4 of the studies testing vedolizumab in Colitis, Ulcerative that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
| NCT03221036Phase 3TakedaEfficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis | 2027-09-24 |
| NCT06581328TakedaA Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting | 2027-05-01 |
| NCT06095128TakedaA Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) | 2027-07-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 38 studies testing vedolizumab in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 68 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of vedolizumab intravenous (IV) treatment compared to adalimumab subcutaneous (SC) treatment over a 52-week treatment period.
The drug being tested in this study is called vedolizumab. Vedolizumab is being tested to treat people who have ulcerative colitis. This study will look at the stool frequency, rectal bleeding and findings on endoscopy of people who take vedolizumab compared to those who take adalimumab.
The study will enroll approximately 658 participants. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):
All participants will receive 1 intravenous infusion on Day 1 and Weeks 2, 6, 14, 22, 30, 38, and 46. All participants will also receive 4 SC injections on Day 1 or 2 SC injections each on Days 1 and 2, followed by 2 SC injections in 1 day on Week 2 and then 1 SC injection every 2 weeks for up to Week 50. All participants will be asked to record the symptoms of ulcerative colitis in a daily diary.
This multi-center trial will be conducted worldwide. The overall time to participate in this study is 79 weeks. Participants will make approximately 11 visits to the clinic, and will be contacted by telephone 6 months after last dose of study drug for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The participant:
Exclusion Criteria:
Has received any of the following for the treatment of underlying disease within 30 days of randomization:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vedolizumab 300 milligram (mg), infusion, intravenously over 30 minutes on Day 1 and Weeks 2, 6, 14, 22, 30, 38, and 46. Adalimumab placebo-matching injection, subcutaneously on Day 1, Week 2, and every 2 weeks thereafter up to Week 50.
Drug: Vedolizumab · Drug: Adalimumab placebo
Adalimumab 160 mg, injection, subcutaneously on Day 1, adalimumab 80 mg, injection, subcutaneously at Week 2, then adalimumab 40 mg, injection, subcutaneously every 2 weeks thereafter up to Week 50. Vedolizumab placebo-matching infusion, intravenously on Day 1 and Weeks 2, 6, 14, 22, 30, 38, and 46.
Drug: Adalimumab · Drug: Vedolizumab placebo
Vedolizumab infusion
Adalimumab placebo-matching injection
Adalimumab injection
Vedolizumab placebo-matching infusion
Percentage of Participants Who Achieved Clinical Remission
Clinical remission was defined as a complete Mayo score of ≤2 points and no individual subscore \>1 point. The Mayo score was a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consisted of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore was scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).
Time frame: Week 52
Percentage of Participants Who Achieved Mucosal Healing
Mucosal healing was defined as a Mayo score endoscopic subscore of \<= 1 point. The Mayo score was a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consisted of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore was scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).
Time frame: Week 52
Percentage of Participants Who Used Oral Corticosteroids at Baseline Who Discontinued Corticosteroids and Were in Clinical Remission
Corticosteroid-free remission was defined as participants using oral corticosteroids at Baseline (Week 0) who had discontinued oral corticosteroids and were in clinical remission at Week 52. Clinical remission was defined as a complete Mayo score of ≤ 2 points and no individual subscore \> 1 point. The Mayo score was a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consisted of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore was scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).
Time frame: Week 52
Participants took part in the study at 205 investigative sites worldwide from 29 June 2015 up to 18 January 2019.
| Milestone | Adalimumab SC, 160/80/40 mg | Vedolizumab IV 300 mg |
|---|---|---|
| Started | 386 | 385 |
| Safety analysis set | 386 | 383 |
| Completed | 217 | 270 |
| Not completed | 169 | 115 |
| Withdrew: Randomized but not treated | 0 | 2 |
| Withdrew: Pretreatment event/adverse event | 18 | 16 |
| Withdrew: Leukopenia or lymphopenia | 1 | 0 |
| Withdrew: Significant protocol deviation | 4 | 5 |
| Withdrew: Lost to follow-up | 14 | 4 |
| Withdrew: Voluntary withdrawal | 39 | 41 |
| Withdrew: Pregnancy | 1 | 1 |
| Withdrew: Lack of efficacy | 86 | 40 |
| Withdrew: Reason not specified | 6 | 6 |
Clinical remission was defined as a complete Mayo score of ≤2 points and no individual subscore \>1 point. The Mayo score was a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consisted of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore was scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).
| percentage of participants | Adalimumab SC, 160/80/40 mg | Vedolizumab IV 300 mg |
|---|---|---|
| Percentage of Participants Who Achieved Clinical Remission | 22.5 (18.5 to 27.0) | 31.3 (26.7 to 36.2) |
Mucosal healing was defined as a Mayo score endoscopic subscore of \<= 1 point. The Mayo score was a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consisted of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore was scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).
| percentage of participants | Adalimumab SC, 160/80/40 mg | Vedolizumab IV 300 mg |
|---|---|---|
| Percentage of Participants Who Achieved Mucosal Healing | 27.7 (23.3 to 32.5) | 39.7 (34.8 to 44.8) |
Corticosteroid-free remission was defined as participants using oral corticosteroids at Baseline (Week 0) who had discontinued oral corticosteroids and were in clinical remission at Week 52. Clinical remission was defined as a complete Mayo score of ≤ 2 points and no individual subscore \> 1 point. The Mayo score was a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consisted of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore was scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).
| percentage of participants | Adalimumab SC, 160/80/40 mg | Vedolizumab IV 300 mg |
|---|---|---|
| Percentage of Participants Who Used Oral Corticosteroids at Baseline Who Discontinued Corticosteroids and Were in Clinical Remission | 21.8 (14.8 to 30.4) | 12.6 (7.1 to 20.3) |
Collected over From first dose of study drug and up to 126 days after the last dose (Up to 68 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adalimumab SC, 160/80/40 mg | 0/386 (0%) | 53/386 (13.7%) | 114/386 (29.5%) |
| Vedolizumab IV 300 mg | 1/383 (0.3%) | 42/383 (11%) | 103/383 (26.9%) |
| Event | Adalimumab SC, 160/80/40 mg | Vedolizumab IV 300 mg |
|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 25/386 | 19/383 |
| AnaemiaBlood and lymphatic system disorders | 4/386 | 1/383 |
| Abdominal painGastrointestinal disorders | 1/386 | 3/383 |
| Cytomegalovirus infectionInfections and infestations | 1/386 | 3/383 |
| DiarrhoeaGastrointestinal disorders | 0/386 | 2/383 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/386 | 2/383 |
| Nerve root compressionNervous system disorders | 0/386 | 2/383 |
| PneumoniaInfections and infestations | 2/386 | 0/383 |
| Angina pectorisCardiac disorders | 0/386 | 1/383 |
| PericarditisCardiac disorders | 0/386 | 1/383 |
| Event | Adalimumab SC, 160/80/40 mg | Vedolizumab IV 300 mg |
|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 42/386 | 26/383 |
| NasopharyngitisInfections and infestations | 30/386 | 27/383 |
| HeadacheNervous system disorders | 21/386 | 27/383 |
| AnaemiaBlood and lymphatic system disorders | 23/386 | 19/383 |
| Upper respiratory tract infectionInfections and infestations | 17/386 | 20/383 |
Randomized Set included all participants who were randomized into the study, regardless of whether they received any dose of the study drug.
| Age, Continuous(years) | Adalimumab SC, 160/80/40 mg | Vedolizumab IV 300 mg | Total |
|---|---|---|---|
| Mean | 40.5 ± 13.44 | 40.8 ± 13.74 | 40.7 ± 13.59 |
| Sex: Female, Male(Participants) | Adalimumab SC, 160/80/40 mg | Vedolizumab IV 300 mg | Total |
|---|---|---|---|
| Female | 170 | 151 | 321 |
| Male | 216 | 234 | 450 |
| Ethnicity (NIH/OMB)(Participants) | Adalimumab SC, 160/80/40 mg | Vedolizumab IV 300 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 8 | 14 |
| Not Hispanic or Latino | 39 | 23 | 62 |
| Unknown or Not Reported | 341 | 354 | 695 |
| Race (NIH/OMB)(Participants) | Adalimumab SC, 160/80/40 mg | Vedolizumab IV 300 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 11 | 4 | 15 |
| Asian | 30 | 32 | 62 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 3 | 2 | 5 |
| White | 341 | 345 | 686 |
| More than one race | 0 | 2 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Adalimumab SC, 160/80/40 mg | Vedolizumab IV 300 mg | Total |
|---|---|---|---|
| Australia | 3 | 5 | 8 |
| Hong Kong | 1 | 4 | 5 |
| Korea, Republic Of | 19 | 16 | 35 |
| Taiwan, Province Of China | 4 | 1 | 5 |
| Czech Republic | 13 | 8 | 21 |
| Hungary | 16 | 16 | 32 |
| Poland | 78 | 85 | 163 |
| Serbia | 11 | 18 | 29 |
| Slovakia | 5 | 8 | 13 |
| Bosnia | 2 | 1 | 3 |
| Bulgaria | 10 | 6 | 16 |
| Croatia | 11 | 5 | 16 |
| Israel | 9 | 13 | 22 |
| Romania | 6 | 6 | 12 |
| Russia | 41 | 44 | 85 |
| Turkey | 9 | 5 | 14 |
| Ukraine | 26 | 39 | 65 |
| Canada | 18 | 20 | 38 |
| United States | 42 | 29 | 71 |
| Argentina | 1 | 3 | 4 |
| Colombia | 2 | 2 | 4 |
| Mexico | 9 | 3 | 12 |
| France | 4 | 6 | 10 |
| Germany | 3 | 6 | 9 |
| Italy | 9 | 11 | 20 |
| Latvia | 6 | 7 | 13 |
| Lithuania | 7 | 7 | 14 |
| Portugal | 9 | 4 | 13 |
| United Kingdom | 2 | 3 | 5 |
| Denmark | 8 | 3 | 11 |
| Belgium | 0 | 1 | 1 |
| Netherlands | 1 | 0 | 1 |
| Spain | 1 | 0 | 1 |
| Height(cm) | Adalimumab SC, 160/80/40 mg | Vedolizumab IV 300 mg | Total |
|---|---|---|---|
| Mean | 170.5 ± 9.65 | 172.0 ± 9.90 | 171.3 ± 9.79 |
| Weight(kg) | Adalimumab SC, 160/80/40 mg | Vedolizumab IV 300 mg | Total |
|---|---|---|---|
| Mean | 73.43 ± 18.374 | 72.67 ± 16.952 | 73.05 ± 17.673 |
| Body Mass Index (BMI)(kg/m^2) | Adalimumab SC, 160/80/40 mg | Vedolizumab IV 300 mg | Total |
|---|---|---|---|
| Mean | 25.17 ± 5.646 | 24.46 ± 4.786 | 24.82 ± 5.244 |
2 further baseline measures are reported on the registry.
Showing the first 100 of 330 sites across 34 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Ran from Jun 2015 to primary completion in Sep 2018, 38 months.
Results were first posted in Oct 2019, 1 year after primary completion.
Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 38 months is below that.
Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vedolizumab